Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Torii Aims to Turn Profit in 2022, Forecasting Revenue Drop after Gilead HIV Pact Ends
February 8, 2019
- Torii to Sell Futhan to Nichi-Iko after 43% Off-Patent Price Slash
February 7, 2019
- Goichi Matsuda Named as New President of Torii
February 7, 2019
- Torii Launches Early Retirement Program as Part of Restructuring Plan
February 7, 2019
- Daiichi Sankyo’s Cancer Med Pexidartinib Gets Priority Review in US
February 7, 2019
- Kyowa Kirin Commences Japan PII Study of NHE3 Inhibitor for Hyperphosphatemia
February 7, 2019
- JCR, Teijin Launch Japan PI/PII of Regenerative Medicine Product for Cerebral Infarction
February 7, 2019
- Kyowa Kirin to Delay 100 Billion Yen Profit Goal, Plans 1st Voluntary Redundancy Program
February 6, 2019
- Kyowa Kirin Sales Slip 1.9% in 2018, but Profit Up on One-Off Factors
February 6, 2019
- Kyowa Kirin to Market Hisamitsu’s Transdermal Parkinson’s Drug
February 6, 2019
- Taiho Licenses Novel EGFR-TKI to US Firm Outside Japan
February 6, 2019
- Q3 Earnings Rundown: Eisai, Takeda, Ono, and More
February 5, 2019
- Ichiro Watanabe to Head Up Teijin Pharma
February 5, 2019
- Oropharyngeal Candidiasis Drug Oravi Now Available in Japan
February 4, 2019
- Takeda Drops US Filing for Ninlaro Label Expansion, Plans Resubmission with OS Data
February 4, 2019
- Keytruda Beats Opdivo in Q4 Global Sales including Asia
February 4, 2019
- Sawai and 7 Other Generic Makers Seeking Lyrica Patent Invalidity
February 4, 2019
- Chugai Plays It Safe with New 3-Year Plan on Consecutive Re-Pricing, Eyes 7-9% Annual EPS Growth
February 1, 2019
- Oncolys Plans to Begin Japan PII Study of Oncolytic Virus in 2nd Half of 2019
February 1, 2019
- Chugai Renews Record Earnings in 2018 on New Drugs, Exports
February 1, 2019
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…